Psoriasis, Depression, and Inflammatory Overlap: A Review.

Area of Science:

• Immunodermatology
• Psychoneuroimmunology
• Clinical Therapeutics

Background:

• Psoriasis significantly impacts patient quality of life, frequently co-occurring with depression.
• Depression in psoriasis may stem from elevated proinflammatory cytokines, suggesting an inflammatory link beyond psychosocial factors.
• Biologic therapies targeting inflammatory cytokines for psoriasis may also influence associated depression.

Purpose of the Study:

• To examine the inflammatory overlap between psoriasis and depression.
• To review clinical studies assessing depression as an outcome in psoriasis patients treated with biologics.
• To highlight the need for standardized depression screening in future psoriasis research.

Main Methods:

• Review of existing literature on psoriasis, depression, and biologic therapies.
• Examination of the pathophysiology linking inflammation and depression.
• Analysis of clinical trial data assessing depression outcomes in psoriasis patients.

Main Results:

• Multiple biologics have demonstrated decreased depression symptoms in psoriasis clinical trials.
• Current studies utilize varied depression screening tools, hindering direct comparison of treatment efficacy.
• Distinguishing direct anti-inflammatory effects from indirect improvements in psoriasis severity on depression is challenging.

Conclusions:

• There is a significant inflammatory link between psoriasis and depression.
• Biologics targeting inflammation show promise in alleviating depression in psoriasis patients.
• Standardized depression screening tools are crucial for future research to enable reliable comparisons across biologic treatments.